Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL925413 | 0.82 | LNPEP (0.33) | CYP2D6CYP1A2CYP2C19MAPK1LNPEP | |
| SCHEMBL924613 | 0.82 | SLC6A4 (0.37) | CYP2D6SLC6A4CYP1A2CYP2C19MAPK1 | |
| SCHEMBL925088 | 0.78 | KDM4E (0.38) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL533960 | 0.78 | CYP2D6 (0.42) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL924693 | 0.75 | NOS3 (0.35) | CYP2D6SLC6A4CYP1A2CYP2C19KDM4E | |
| SCHEMBL3720544 | 0.75 | CYP2D6 (0.33) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL3720545 | 0.72 | CYP2D6 (0.32) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL3720537 | 0.72 | HTR1A (0.33) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL3720541 | 0.72 | CYP2D6 (0.32) | CYP2D6HTR1ASLC6A4CYP1A2CYP2C19 | |
| SCHEMBL534207 | 0.71 | SLC6A4 (0.40) | CYP2D6HTR1ASLC6A4MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009399-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2231677-A2 | TRISUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074674-A2 | TRISUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009399-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CYP2D6 71/4885HTR1A 976/4885SLC6A4 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.